Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary Objective: • To demonstrate that the combination of sunitinib plus erlotinib is superior to erlotinib plus placebo in prolonging the overall survival for advanced/metastatic NSCLC patients who have received 1 to 2 prior chemotherapy regimens.
Critère d'inclusion
- Locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen